Trial Profile
Phase II study of dasatinib for CML-CP patients with suboptima/failure after treatment of imatinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2015
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 20 Dec 2011 New trial record